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ABSTRACT
Amyotrophic lateral sclerosis (ALS) rarely presents with hyponatraemia caused by syndrome of inappropriate antidiuretic hormone secretion 
(SIADH). We present a patient with hyponatraemia of multifactorial aetiology, in whom, after withdrawal of the drugs that contributed to 
this ionic alteration, SIADH secondary to ALS was confirmed. After initiating treatment with urea, sodium levels were normalized.
LEARNING POINTS
• Amyotrophic lateral sclerosis (ALS) is rarely associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH).
• In a patient with chronic hyponatraemia due to SIADH, administration of urea, as recommended by clinical practice guidelines, increases 
sodium levels.
• We present the case of a patient with SIADH due to ALS where hyponatraemia was resolved using urea.
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CASE DESCRIPTION
An 83-year-old male with a history of type 2 diabetes mellitus, high blood pressure and dyslipidemia was diagnosed with amyotrophic lateral 
sclerosis (ALS) by our neurology service, with dysarthria as the main manifestation, and treatment with riluzole was initiated. Functional 
tests showed a moderate restrictive pattern, although without respiratory symptoms.
Three months later, the patient was admitted to the internal medicine service due to a deterioration in his general condition in the previous 
week, nausea with isolated vomiting, decreased food intake and postural instability. He was taking gliclazide, metformin, irbesartan/
hydrochlorothiazide, nifedipine, simvastatin, riluzole, omeprazole, escitalopram and lorazepam. There were no respiratory symptoms 
and baseline oxygen saturation was 93%. The physical examination showed only a widespread loss of strength, which had appeared in the 
previous 2 months. In the initial analysis, sodium levels of 120 mmol/l (confirmation with sodium levels of 117) and plasma osmolality of 232 
mOsm/kg (normal values 280–300) were the most notable findings. 
After discontinuing the thiazide and the 2 drugs associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH), 
escitalopram and omeprazole, sodium levels were 127 mmol/l and osmolality was 263 mOsm/kg; potassium, venous blood gas, cortisol and 
TSH were normal, and urine sodium was 46 mmol/l with an osmolality of 560 mOsm/kg, confirming the diagnosis of SIADH. The study of 
other possible causes of SIADH was negative, including chest x-ray, cranial CT and chest-abdominal CT. 
With the withdrawal of the drugs involved in hyponatraemia and fluid restriction, the symptoms that had appeared in the week before 
admission remitted. At discharge, the patient began treatment with a daily sachet of 15 g of urea and in the follow-up visit at 7 days, sodium 
levels had normalized to 136 mmol/l.
European Journal
of Case Reports in
Internal Medicine
DOI: 10.12890/2020_001444 European Journal of Case Reports in Internal Medicine © EFIM 2020
DISCUSSION
ALS rarely presents with hyponatraemia, and when it does so, this is due to SIADH[1–3]. It has been suggested that restrictive respiratory 
failure secondary to respiratory muscle atrophy may be responsible for SIADH in these patients[1]. In reported cases, hyponatraemia 
was resolved with mechanical ventilation[1], non-invasive ventilation[2] or tolvaptan[3]. The administration of urea for SIADH has not been 
previously described.
In patients with SIADH, urea administration increases the urinary excretion of solutes and water, significantly raising sodium levels; it may 
be used chronically, and therefore, despite the lack of placebo-controlled clinical trials, its use is recommended by European clinical practice 
guidelines on hyponatremia[4], which do not advise the use of vaptans, although controversy remains regarding this point[5]. Urea has not 
been widely used as it was not available in pharmacies. However, it is currently sold in several countries in sachets containing 15 g of urea in 
powder form for oral solution with administration every 12–24 hours, and has the advantage that tolerance is better than that for tolvaptan 
[4], which is why it was decided to use it in this patient. 
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